I. Collect human tumor tissue and other biological specimens (blood, serum, and bone marrow)
from patients with rhabdomyosarcoma or non-rhabdomyosarcoma soft tissue sarcoma diagnosed
and/or treated at a Children's Oncology Group (COG) member institution.
II. Provide a repository for storage of tissue and other biological specimens collected by
COG investigators from these patients.
III. Make these specimens available for approved projects by laboratory-based investigators.
IV. Collect clinical data on these patients who are not being treated on a COG therapeutic
V. Define and compare the clinical features of patient subgroups with alveolar
rhabdomyosarcoma whose tumors carry the t(2;13), t(1;13) or neither translocation.
VI. Investigate the relationship between evidence of submicroscopic disease and response rate
(CR/PR), failure-free survival, and survival of patients with alveolar rhabdomyosarcoma, as
determined by positive or negative reverse transcriptase-polymerase chain reaction (RT-PCR)
assay for the t(2:13) and t(1:13) on peripheral blood and bone marrow specimens obtained at
VII. Compare the clinical, cytogenetic, and molecular biologic features of patient subgroups
with anaplastic rhabdomyosarcoma and other subtypes of rhabdomyosarcoma.
Surgical tissue, bone marrow, and blood specimens are collected at diagnosis (initial or
relapse) and, if applicable, at the development of a second primary tumor. Specimens are used
for research purposes. A certificate of confidentiality protecting the identity of research
participants in this project has been issued by the National Cancer Institute.
Patients who are not enrolled on a Children's Oncology Group treatment trial are followed
every 6 months for at least 10 years or until disease progression or development of a second